Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

It is well established that multifactorial drug resistance hinders successful cancer treatment.
Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial …

The successful treatment of cancer has significantly improved as a result of targeted therapy
and immunotherapy. However, during chemotherapy, cancer cells evolve and can acquire …

Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Cancer cells employ both conventional oxidative metabolism and glycolytic anaerobic
metabolism. However, their proliferation is marked by a shift towards increasing glycolytic …

Breast cancer is one of the most prevalent cancers in women and a leading cause of
mortality. As per the GLOBCAN report of 2021, breast cancer has surpassed lung cancer …

Drug resistance is a major obstacle in the field of pre-clinical and clinical therapeutics. The
development of novel technologies and targeted therapies have yielded new modalities to …

Cancer is one of the main public health problems in the world. Systemic therapies such as
chemotherapy and more recently target therapies as well as immunotherapy have improved …

Widespread drug resistance has become the key issue in global healthcare. Extensive
efforts have been made to reveal not only diverse diseases experiencing drug resistance …

Despite the development of targeted therapy, drug resistance remains a primary hindrance
to curative treatment of various cancers. Among several novel approaches to overcome drug …